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Abstract Tangier disease (TD) is an inherited disorder of lipid
metabolism characterized by very low high density lipoprotein
(HDL) plasma levels, cellular cholesteryl ester accumulation and
reduced cholesterol excretion in response to HDL apolipopro-
teins. Molecular defects in the ATP binding cassette transporter
1 (ABCA1) have recently been identified as the cause of TD.
ABCA1 plays a key role in the translocation of cholesterol across
the plasma membrane, and defective ABCA1 causes cholesterol
storage in TD cells. Not only cholesterol efflux, but also
phospholipid efflux was shown to be impaired in TD cells. By use
of thin layer chromatography, high performance liquid chroma-
tography and time-of-flight secondary ion mass spectrometry, we
characterized the cellular phospholipid content in fibroblasts
from three homozygous TD patients. The cellular content of the
major phospholipids was not found to be significantly altered in
TD fibroblasts. However, the two phospholipids cardiolipin and
lysocardiolipin, which make up minute amounts in normal cells,
were at least 3^5-fold enriched in fibroblasts from TD subjects. A
structurally closely related phospholipid (lysobisphosphatidic
acid) has recently been shown to be enriched in Niemann^Pick
type C, another lipid storage disorder. Altogether these data may
indicate that the role of these phospholipids is a regulatory one
rather than that of a bulk mediator of cholesterol solubilization
in sterol trafficking and efflux. ß 2001 Federation of Euro-
pean Biochemical Societies. Published by Elsevier Science B.V.
All rights reserved.
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1. Introduction
High density lipoprotein (HDL) plays an important role in
reverse cholesterol transport, the process by which the choles-
terol is transported from peripheral cells to the liver, where it
is excreted in the form of bile salts. This process is thought to
protect against the development of atherosclerosis. The cho-
lesterol e¥ux process involves speci¢c and unspeci¢c mecha-
nisms [1,2]. Speci¢c cholesterol e¥ux from cells is mediated by
HDL apolipoproteins; it involves the activation of cellular
phospholipases and kinases and an active brefeldin-sensitive
transport pathway [3^6]. The speci¢c apolipoprotein-inducible
cholesterol e¥ux is severely impaired in subjects with homo-
zygous Tangier disease (TD) [7^10], resulting in almost com-
plete absence of circulating HDL, massive accumulation of
cholesteryl esters in many tissues and an increased cardiovas-
cular risk [11^13].
The ATP binding cassette transporter 1 (ABCA1) was re-
cently identi¢ed as the molecular defect in TD by genetic
mapping [14] and subsequent sequencing of candidate genes
on DNA from Tangier patients [15^18]. The ATP binding
cassette superfamily is comprised of a large group of evolu-
tionarily conserved proteins present in prokaryotes and eu-
karyotes [19]. These proteins function by coupling the hydro-
lysis of ATP to the transmembrane £ux of a wide variety of
substrates across organellar and plasma membranes. ABCA1
seems to be an essential cofactor for the translocation of cho-
lesterol from intra- to extracellular sites [20], and defective
ABCA1 in TD thus impairs apolipoprotein-mediated choles-
terol translocation to and across the plasma membrane. How-
ever, the exact mechanism of ABCA1-dependent and alterna-
tive cholesterol excretion pathways is not clear.
In addition to this defect phospholipid e¥ux was shown to
be impaired in radiolabeled TD ¢broblasts [8]. Remaley et al.
[21] hypothesized that phospholipid and cholesterol e¥ux are
closely related. They proposed the following model: apolipo-
protein A-I (apo A-I) ¢rst removes phospholipids by direct
interaction with the plasma membrane; in the second step the
resulting apo A-I phospholipid complex is able to accept cho-
lesterol. We have used thin layer chromatography (TLC), high
performance liquid chromatography (HPLC) and time-of-
£ight secondary ion mass spectrometry (TOF-SIMS) to char-
acterize the cellular phospholipid content in ¢broblasts from
homozygous TD patients. The cellular concentration of the
major phospholipids was not altered in TD cells. By contrast,
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two minor phospholipids, cardiolipin (CL) and lysocardiolipin
(LC), were enriched at least 3^5-fold.
2. Materials and methods
2.1. Probands
The experiments were performed with ¢broblasts from three nor-
molipidemic healthy probands and the three homozygous Tangier
patients, TD1 (66 years, male), TD2 (64 years, male) and TD3 (63
years, female, sister of TD1), whose clinical, biochemical and genetic
characteristics have been described in detail in previous reports
[4,7,11,12,22^25]. Patients TD1 and TD3 are characterized by an as-
paragine to serine mutation at position 935 of ABCA1 [25]. The un-
related patient TD2, who su¡ers from severe premature atherosclero-
sis, has a stop codon mutation at position 575 of the ABCA1 gene,
predicting truncation of the encoded ABCA1 protein and deletion of
most of the protein sequence, including both ATP binding cassettes
[15].
2.2. Reagents
L-Lyso-3-phosphatidylcholine was obtained from Amersham Corp.
(Braunschweig, Germany). All lipid standards were obtained from
Avanti Polar Lipids (Alabaster, AL, USA). Autoradiography was
performed by using Kodak X-OMAT ¢lm (Eastman Kodak, Roches-
ter, NY, USA). Medium components were obtained from Flow Lab-
oratories (Meckenheim, Germany). Plastic culture dishes were pur-
chased from Falcon Labware (Oxnard, CA, USA), scintillation
counting mixture (Ultima-Gold) was obtained from Canberra-Pack-
ard (Frankfurt, Germany). Aluminum-backed silica gel 60 TLC plates
and the solvents for TLC, HPLC and MS were purchased from
Merck (Darmstadt, Germany). All other reagents were obtained
from Sigma Chemical Co. (Deisenhofen, Germany) and were of the
highest purity available.
2.3. Cell culture
Human skin ¢broblasts cultured from biopsies of adult human hip
skin were grown and maintained in Dulbecco’s modi¢ed Eagle’s me-
dium (DMEM) containing 10% fetal calf serum, 2 mM L-glutamine,
and 1% antibiotic/antimycotic solution (Sigma Chemical Co., St.
Louis, MO, USA), as previously described [7]. Once separated, the
dermis was cut into small pieces (0.5 mm on each side) and placed in a
£ask in DMEM. When these primary cultures were con£uent they
were expanded by passage. Experiments were routinely performed
with cells between passage levels three and six. Under these condi-
tions, the TD cells display their typical characteristics such as choles-
terol accumulation and markedly reduced cholesterol e¥ux [7]; how-
ever, the growth rate (which was reported to be reduced at higher cell
passages) was not signi¢cantly reduced. The cells were seeded in 60-
mm culture dishes at a density of V7.5U104/dish. The state of 70^
80% con£uence was reached after 3^4 days. The cell layers were rinsed
twice with phosphate-bu¡ered saline (PBS, pH 7.4) and used for mea-
surements.
2.4. Radiolabeling and separation of radiolabeled phospholipids by TLC
At the state of near-con£uence the cell layers were rinsed twice with
PBS (pH 7.4) and incubated for 48 h at 37‡C in DMEM. After 48 h,
the medium was removed, the cells were washed three times with PBS
and incubated for 2 h in 2 ml of DMEM^HEPES containing 0.05
WCi/ml [1-14C]palmitoyl-L-lyso-3-phosphatidylcholine (56 mCi/mmol)
as previously described [3,4]. Thereafter, cells were washed ¢ve times
in PBS, and incubated for an additional 3 h in 2 ml of DMEM^
HEPES. The medium was removed and the cell dishes were placed
in a liquid nitrogen bath. The cells were scraped from the dishes with
a rubber policeman, once with 2 ml of ice-cold methanol and once
with 2 ml of ice-cold distilled water. Radioactive lipids were extracted
by the method of Folch et al. [26]. The cellular protein content was
measured according to Bradford [27].
For TLC analysis we used a double one-dimensional technique to
separate phospholipids of interest, as described in detail in reference
[4]. In this approach, a series of samples were spotted 12 cm from the
bottom of a 20U20 cm TLC plate. In order to separate neutral lipids
from phospholipids that remained at the origin, the plates were twice
developed in toluene/ether/ethanol/triethylamine (100:80:4:2, per vol).
After the ¢rst run to 20 cm, the plates were thoroughly dried and
developed a second time with the same solution to 18 cm. Plates were
then cut 0.8 cm above the origin (i.e. 12.8 cm above the lower edge of
the plate), rotated 180‡, and developed to the top with chloroform/
methanol/ammonium hydroxide (65:35:5, per vol). After they were
dried thoroughly, autoradiography was performed by using Kodak
X-OMAT ¢lm for 7^14 days. Radioactive bands were cut from the
silica plates, placed in scintillation vials containing 10 ml Ultima-Gold
scintillation £uid, and quantitated by liquid scintillation counting in a
scintillation counter (model 1214; LKB, Bromma, Sweden). The iden-
tities of labeled bands were determined by comparing the Rf values
with those of reference substances, visualized by iodine staining.
2.5. Preparation of radiolabeled LC standards
Mono-LC and di-LC were prepared by phospholipase hydrolysis of
radiolabeled CL. To this purpose, ¢broblasts were incubated with
[1-14C]palmitoyl-L-lyso-3-phosphatidylcholine (0.1 WCi/dish), lipids
were isolated and separated by TLC as described before. The CL
band was scraped o¡ the plate, extracted with chloroform and dried
under a stream of nitrogen. The residue was redissolved in 2 ml 0.05
Tris^HCl (pH 7.4), incubated for 4 h (37‡C) with Rhizopus arrhizus
phospholipase (30 000 units, purchased from Sigma, Deisenhofen,
Germany), extracted and separated by TLC as described before.
2.6. MS and HPLC
After incubation of the ¢broblasts for 48 h at 37‡C in DMEM, the
medium was removed, the cells were washed three times with PBS and
incubated for 2 h in 2 ml of DMEM^HEPES, containing 500 Wg/ml
lysophosphatidylcholine (egg). After extraction of lipids by the meth-
od of Folch et al. [26] phospholipids were separated by HPLC ac-
cording to Nissen and Kreysel [28]. HPLC fractions were collected
every 2 min and 10 Wl of this fraction was analyzed by mass spec-
trometry using a TOF-SIMS II spectrometer (IONTOF, Mu«nster,
Germany), as previously described [29]. The fraction was applied to
a silver target which had been pre-etched for 2 min with 20% HNO3.
After evaporating the solvent, the sample was bombarded with 40Ar,
1011 ions/cm2 (11 keV). Measurements were performed with typical
acquisition times of 100 s. The approximate mass resolution was M/
vM = 10 000, where M is the target ion mass and vM is the resolved
mass di¡erence at half-width full peak mode. The identity of the
phospholipid species was calculated based on the measured mass
and con¢rmed by comparison with synthetic standards.
3. Results
3.1. Characterization of radiolabeled phospholipids by TLC
To investigate whether there were any abnormalities in the
relative concentrations of radiolabeled phospholipids, control
and TD ¢broblasts were labeled with [1-14C]palmitoyl-L-lyso-
3-phosphatidylcholine, for 2 h at 37‡C, and the cellular lipids
were separated by TLC. This procedure resulted in a quanti-
tative incorporation of label into phospholipids, and no sig-
ni¢cant change of label incorporation was observed from 2 h
up to 10 h onwards. The total amount of radioactivity incor-
porated into cellular lipids and separated on TLC was similar
in TD and control cells (controls: 30 833 þ 2674 dpm/dish;
Tangier: 39 741 þ 7723 dpm/dish, mean þ S.D.). 35^50% of
the radiolabel incorporated was acylated to phosphatidylcho-
line (PC), 30^35% of the radioactivity was found in the tri-
glycerides, V15% in phosphatidylethanolamine (PE), 2^2.5%
in phosphatidic acid (PA), V3% in the lyso-PC (LPC)/phos-
phatidylinositol (PI)/sphingomyelin (SM) fraction, 1^1.5% in
diacylglycerol, and 0.2^0.5% in monoacylglycerol (Fig. 1). The
relative concentrations of these phospholipids were not signif-
icantly di¡erent between patients and controls. Three phos-
pholipids of minor concentration, however, were found to be
at least ¢ve-fold enriched in TD cells (arrows). Only minute
amounts of these phospholipids were present in control cells.
The most hydrophobic phospholipid comigrated with com-
mercially available CL in one- and two-dimensional TLC.
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The other two phospholipids (lower two arrows in Fig. 1)
were indistinguishable by TLC from the two deacylated forms
of CL obtained from CL by incubation with Rhizopus arrhizus
lipase (a lipase with phospholipase A1-like activity; LC1 and
LC2 in Fig. 1). A cochromatographic analysis, in which radio-
active standards and samples were mixed, further con¢rmed
this identi¢cation (data not shown).
3.2. Characterization of phospholipids by HPLC and TOF-
SIMS
Non-radioactive phospholipid content of control and TD
cells was examined by HPLC analysis of cellular lipid extracts.
As shown in Fig. 2, the cellular phospholipid content of con-
trol and TD cells was very similar. We did not ¢nd a signi¢-
cant quantitative di¡erence of the major phospholipid classes.
Mass spectroscopy analysis of the HPLC lipid fractions and
comparison of the masses with a computerized search pro-
gram identi¢ed the major HPLC fractions as PC and PE, as
indicated in Fig. 2. The relatively hydrophobic CL-containing
HPLC fraction was 3^5-fold increased (Fig. 2). Fig. 3 repre-
sents mass spectra of this HPLC fraction in the mass range
1100^1600 amu. In the positive secondary ion mass spectra,
lipid species were detectable in protonated [M+H], cation-
ized [M+Na] or intact [M] forms. The theoretical masses of
the molecular ions of CL (based on tetra-linoleoyl CL) were
as follows: [M], 1447 amu; [M3C6H12], 1363 amu;
[M3C16H29+Na], 1249 amu. Using a computerized lipid li-
brary (composed of 2780 di¡erent masses of phospholipids
and fragments) these molecular masses corresponded exactly
to CL. The identity of this compounds was further con¢rmed
by comparison with mass spectra and HPLC retention times
of commercially available CL (Figs. 2 and 3). Moreover, the
most intense signal in the respective negative spectrum re-
vealed the molecular mass of the fatty acid linoleic acid
([M]3, 280 amu), which is the most abundant fatty acid in
CL. On the basis of the HPLC results for lipid fractions
Fig. 1. A: TLC analysis of cellular lipid extracts from two control
(CON1, CON2) and two Tangier (TD1, TD2) ¢broblast lines la-
beled with 0.05 WCi/ml [1-14C]palmitoyl-L-lyso-3-phosphatidylcholine.
The identities of CL, PE, PC, LPC, PI, PA and SM were deter-
mined with one- and two-dimensional TLC, by comparing the Rf
values with those of commercially available reference substances,
visualized by iodine staining (not shown). Mono-LC (LC1) and di-
LC (LC2) were identi¢ed by comparison with radioactive standards,
which were prepared by phospholipase hydrolysis of radiolabeled
CL, as described in Section 2. The standard shown in the ¢gure
(STD) represents a mixture of radioactive CL, mono-LC (LC1) and
di-LC (LC2), visualized by autoradiography. B: Radioactive
phospholipids were cut from the plate and quanti¢ed by liquid scin-
tillation counting as described in Section 2. Each value represents
the mean ( þ S.E.M.) of n = 12 repetitive experiments from a single
¢broblast culture. *P6 0.01 compared to the appropriate control
value.
Fig. 2. HPLC analysis of phospholipid extracts from one representa-
tive control (CON1) and two Tangier (TD1, TD2) ¢broblast lines.
A: HPLC chromatograms of CON1, TD1, TD2 and the standard
mixture (STD): CL (25 Wg/ml), PE (50 Wg/ml), PC (100 Wg/ml), SM
(50 Wg/ml), PA (25 Wg/ml) and PI (25 Wg/ml). B: Content of phos-
pholipids, estimated by integration of the respective HPLC peaks.
Each value represents the mean ( þ S.E.M.) of n = 6 repetitive experi-
ments from a single ¢broblast culture. *P6 0.01, TD1 vs. CON2,
and TD2 vs. CON2.
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obtained from three separate cellular lipid preparations, the
concentration of CL in TD cells was estimated to be
18.7 þ 1.68 (TD1) and 24.3 þ 2.19 (TD2) Wmol/mg cell protein
in two Tangier cell lines and 5.1 þ 0.46 (CON1) and 5.5 þ 0.49
(CON2) in two control cell lines. Since the CL-containing
HPLC fraction contained minor amounts of additional lipids,
the CL concentration especially in controls tended to be over-
estimated. On the basis of MS, the CL concentration in con-
trols was close to the lower detection limit of TOF-SIMS both
in the positive (Fig. 3) and in the negative spectrum (data not
shown). Also, CL was not detectable at higher concentrations
in any other HPLC fraction in controls.
4. Discussion
The cellular cholesterol content is markedly increased in
TD ¢broblasts [8], probably due to impaired translocation
of cholesterol across the plasma membrane [7^10]. It has pre-
viously been shown that not only cholesterol e¥ux but also
phospholipid e¥ux is defective in TD ¢broblasts [8,21]. Since
ATP binding cassette transporters are involved in the trans-
membrane £ux of a wide variety of substrates, we hypothe-
sized that cholesterol and phospholipid mass e¥ux might be
coordinately regulated, and thus that both processes might be
impaired leading to signi¢cant cellular accumulation of phos-
pholipids.
The novel ¢nding provided by this investigation is that in
TD ¢broblasts the content of CL and LC is severalfold in-
creased as compared to normal ¢broblasts. However, we
could not detect signi¢cant di¡erences in the cellular content
of major cellular phospholipids of normal and TD ¢broblasts.
Of course, these data do not exclude the possibility that a
quantitatively minor fraction of cellular PC is e¥uxed togeth-
er with cholesterol and is required for the solubilization of
Fig. 3. TOF-SIMS spectrum of the CL fraction from control and TD cells. The characteristic CL fragments are presented in the insert of
CON1.
Fig. 4. Molecular structure of lyso-bis-PA and di-LC.
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cholesterol. Moreover, it is possible that phospholipid accu-
mulation, comparable to cholesterol accumulation, is pre-
vented by decreased synthesis or enhanced catabolism of cel-
lular phospholipids. The accumulation of two quantitatively
minor phospholipids in TD ¢broblasts suggests that phospho-
lipids may play a regulatory role in cellular cholesterol sorting
and tra⁄cking rather than acting solely via solubilization of
cholesterol. Two possibilities may account for the cellular ac-
cumulation of (lyso)CL in TD. First, the translocation of
cellular cholesterol is closely related to translocation of (ly-
so)CL and both processes are coordinately regulated and im-
paired in TD. Second, enhanced synthesis and/or accumula-
tion of CL may re£ect enhanced mitochondrial activity,
possibly as the result of an adaptive mechanism.
CL is ubiquitous in eukaryotes. It is unique in structure,
subcellular localization and potential function. Because it is
found predominantly in the mitochondrial inner membrane, it
is an excellent marker for mitochondrial biogenesis. Its func-
tion, however, has remained unclear ever since it was discov-
ered in the 1940s [30]. CL was proposed to be an important
cofactor for cholesterol translocation from the outer to the
inner mitochondrial membrane where it enhances the avail-
ability of cytochrome P-450 to inner membrane cholesterol
[31,32]. In steroidogenic tissues, CL activates mitochondrial
cholesterol side chain cleavage and is a potent stimulator of
steroidogenesis. Recent data from Bjo«rkhem’s group suggest
that mitochondrial cholesterol oxidation may also occur in
non-steroidal cells to enhance the cholesterol solubility and
to stimulate cholesterol e¥ux [33,34]. Moreover, oxysterols
are physiological ligands of nuclear hormone receptors (liver
X receptors), which may play an important role in reverse
cholesterol transport [35]. Mitochondrial cholesterol oxidation
may therefore represent a defence mechanism for removal of
excess cholesterol, and could be a¡ected in TD cells.
It is striking that the structure of (lyso)CL is closely related
to the structure of lyso-bis-PA (Fig. 4). Lyso-bis-PA accumu-
lates in ¢broblasts from patients with Niemann^Pick type C
(NPC) disease, another cholesterol storage disease. Mutations
in the NPC1 gene result in accumulation of low density lipo-
protein-derived cholesterol in endosomes and lysosomes,
which cholesterol cannot be translocated to the plasma mem-
brane [36,37]. The translocation of endogenously synthesized
cholesterol to and across the plasma membrane (which is de-
fective in TD) seems to be normal in NPC1-de¢cient cells [38].
Defective cholesterol storage in late endosomes and lysosomes
secondarily leads to a redistribution of membrane proteins
and phospholipids. In this context, it was hypothesized that
lyso-bis-PA (by means of its unique structure and physico-
chemical properties) is a key player in the regulation of sort-
ing and tra⁄cking of lipids [39^41]. Based upon our data it is
possible that a variety of such regulatory phospholipids may
exist. Thus, further characterization of phospholipids in TD
and other lipid storage disorders could be helpful for elucida-
tion of sterol tra⁄cking, which process is poorly understood
at the molecular level.
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